Cogstate (ASX:CGS): How Are Mood-Disorder Trials Changing Its Contract Mix?

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Cogstate (ASX:CGS): How Are Mood-Disorder Trials Changing Its Contract Mix?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cogstate (ASX:CGS) signed US$25.1 million in 1Q27 net sales contracts.
Five Phase III mood-disorder trials represented more than 80% of quarterly contract value.
FY26 Revenue reached US$60.9 million, according to the annual report.
Total contracted revenue at September 2026 was US$143.7 million.

Cogstate Limited (ASX:CGS) provides digital cognitive assessments, clinical outcome measurement and related services for neuroscience drug trials and healthcare applications. The company's ASX-listed shares traded at AUD 3.80 on 12 November 2026, up 4.40% during the session. Its October Business update outlined US$25.1 million in new first-quarter FY27 contract sales, with large late-stage mood-disorder trials playing a substantial role in the result and shifting the timing of potential revenue recognition.

Digital Assessments in Clinical Research

Cogstate (ASX:CGS) works with drug developers undertaking central nervous system research, where consistent measurement of cognition and other clinical outcomes is important to trial execution. Its activities include cognitive testing, rater training, data-quality programs and related services. The company also serves healthcare customers using digital cognitive assessment tools. Contract scope varies by trial phase, number of participants, duration and required technologies. Consequently, the announcement of a contract is not equivalent to an immediate revenue receipt; trial activities and contractual milestones determine the timing of recognition.

September-Quarter Contract Sales

For the three months ended 30 September 2026, Cogstate (ASX:CGS) executed US$25.13 million in net sales contracts, compared with US$21.42 million in the corresponding quarter. The company identified five Phase III trials in bipolar disorder or depression across two customers as contributing more than 80% of the quarterly contract total. Its distribution approach allows sponsors to retain preferred clinical technology providers while using Cogstate's endpoint measurement services. The concentration of a large portion of sales in a small number of study awards is relevant when interpreting one quarter in isolation.

Contracted Revenue and Recognition Timing

At 30 September 2026, Cogstate (ASX:CGS) reported total contracted revenue of US$143.7 million, against US$101.8 million a year earlier. Contracted revenue attributed to FY27 had increased to US$56.8 million from US$48.3 million at the preceding June balance date. The first quarter's new contracts added US$8.4 million to FY27 contracted revenue, representing an in-year Yield of 34%. The company linked this lower-than-usual yield partly to longer-duration Phase III work and a smaller licensing component. Contracted revenue can cover multiple years and should not be confused with cash already received or revenue recognised in the quarter.

FY26 Financial Performance

Cogstate (ASX:CGS) reported US$60.9 million in FY26 revenue, compared with US$53.1 million in the preceding financial year. Earnings before interest, tax, Depreciation and Amortisation were US$18.3 million, while net profit after tax was approximately US$11.9 million. FY26 net sales contracts totalled US$89.0 million. These results provide the financial context for its first-quarter FY27 update, but the latter focused principally on contract wins and contracted future revenue rather than a complete new profit-and-loss statement.

Customer Mix and Delivery Risks

The first-quarter mix showed material exposure to mood-disorder development programs. Cogstate (ASX:CGS) noted that license fees represented 7% of its new quarter contracts, below its cited historical average range of 20%–25%. Longer Phase III trials can spread revenue over extended periods and expose delivery to sponsor timelines, patient enrolment, protocol changes and contract adjustments. The company's ability to staff and execute complex multinational studies also affects the conversion of signed work into recorded revenue. Later contract and financial updates will provide a better test of the durability of this sales mix.

Key Insights

Cogstate (ASX:CGS) entered FY27 with higher reported contracted future revenue and a September-quarter sales result dominated by five mood-disorder Phase III trials. Its FY26 revenue and earnings offer an established baseline, while the quarter's lower in-year revenue yield illustrates how contract duration matters. Future assessment can focus on study execution, revenue conversion and the mix of neurological research areas in newly signed contracts.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.